KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Halozyme Therapeutics (HALO) Assets (2016 - 2025)

Halozyme Therapeutics (HALO) has disclosed Assets for 16 consecutive years, with $2.2 billion as the latest value for Q3 2025.

  • On a quarterly basis, Assets rose 4.87% to $2.2 billion in Q3 2025 year-over-year; TTM through Sep 2025 was $2.2 billion, a 4.87% increase, with the full-year FY2024 number at $2.1 billion, up 19.05% from a year prior.
  • Assets was $2.2 billion for Q3 2025 at Halozyme Therapeutics, up from $2.2 billion in the prior quarter.
  • In the past five years, Assets ranged from a high of $2.2 billion in Q3 2025 to a low of $966.6 million in Q1 2021.
  • A 5-year average of $1.7 billion and a median of $1.8 billion in 2022 define the central range for Assets.
  • Peak YoY movement for Assets: skyrocketed 126.21% in 2021, then dropped 5.88% in 2023.
  • Halozyme Therapeutics' Assets stood at $1.1 billion in 2021, then soared by 66.74% to $1.8 billion in 2022, then fell by 5.88% to $1.7 billion in 2023, then grew by 19.05% to $2.1 billion in 2024, then rose by 7.65% to $2.2 billion in 2025.
  • Per Business Quant, the three most recent readings for HALO's Assets are $2.2 billion (Q3 2025), $2.2 billion (Q1 2025), and $2.1 billion (Q4 2024).